Epidermolysis Bullosa (EB) Market Outlook

Thelansis’s “Epidermolysis Bullosa (EB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epidermolysis Bullosa treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Epidermolysis Bullosa (EB) Overview

Epidermolysis bullosa (EB) is a rare, devastating group of inherited mechanobullous disorders characterised by extreme skin fragility and blister formation following minimal mechanical trauma, caused by mutations in genes encoding structural proteins of the dermal-epidermal junction — including keratins 5 and 14 in EB simplex, collagen XVII and laminin-332 in junctional EB, and collagen VII in dystrophic EB — disrupting epidermal adhesion at distinct ultrastructural levels. Disease severity ranges from localised blistering in EB simplex to profoundly debilitating phenotypes in recessive dystrophic EB and Kindler syndrome, with extracutaneous manifestations including oesophageal strictures, corneal erosions, anaemia, and malnutrition compounding morbidity. Diagnosis integrates clinical phenotyping, immunofluorescence antigen mapping, transmission electron microscopy, and confirmatory genetic panel testing. Wound care — non-adherent dressings, infection control, and blister management — alongside nutritional optimisation and pain management remain therapeutic cornerstones. Beremagene geperpavec, a topical COL7A1 gene therapy, represents a landmark approved advance specifically for recessive dystrophic EB wounds. Losartan demonstrates emerging anti-fibrotic efficacy via TGF-β inhibition in dystrophic EB, while dupilumab and nemolizumab address refractory pruritus in severe disease. Oesophageal dilatation, ophthalmological surveillance, and regular squamous cell carcinoma screening are essential. Prognosis varies with subtype; multidisciplinary wound care, psychosocial support, and genetic counselling are indispensable to compassionate long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)